105 related articles for article (PubMed ID: 25368293)
1. Multi-targeted approach to cancer treatment: an international translational cancer research symposium.
Mehta K; Gandhi V; Pathak S; Aggarwal BB; Grover RK
Anticancer Res; 2014 Nov; 34(11):6791-5. PubMed ID: 25368293
[TBL] [Abstract][Full Text] [Related]
2. Meeting report: leaders in translational cancer research meet in Udaipur, a historical town of India: an International Symposium onTranslational Cancer Research: Cancer Prevention. Udaipur, Rajasthan, India, december 16-19, 2011.
Gandhi V; Mehta K; Pathak S; Aggarwal BB
Anticancer Res; 2013 Apr; 33(4):1777-81. PubMed ID: 23564834
[TBL] [Abstract][Full Text] [Related]
3. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
Bellail AC; Hao C
Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
[No Abstract] [Full Text] [Related]
4. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
5. Prevention and Treatment of Cancer: Hypes and Hopes 6th International Translational Cancer Research Conference.
Patel P; Vora H; Aggarwal BB; Gandhi V; Mehta K; Pathak S
Anticancer Res; 2016 Sep; 36(9):4971-5. PubMed ID: 27630358
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathways: targeting inhibitor of apoptosis proteins in cancer--from molecular mechanism to therapeutic application.
Fulda S
Clin Cancer Res; 2014 Jan; 20(2):289-95. PubMed ID: 24270683
[TBL] [Abstract][Full Text] [Related]
7. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
8. Dual HER2-targeted approaches in HER2-positive breast cancer.
Ahn ER; Vogel CL
Breast Cancer Res Treat; 2012 Jan; 131(2):371-83. PubMed ID: 21956210
[TBL] [Abstract][Full Text] [Related]
9. City of temples discusses signaling templates in cancer cells. Third International Symposium on Translational Cancer Research: Cell Signaling & Cancer Therapy. Bhubaneswar, Orissa, India, December 18th through 21st, 2009.
Gandhi V; Mehta K; Pathak S; Ravindran B; Mishra S; Aggarwal BB
Anticancer Res; 2010 Jun; 30(6):2477-80. PubMed ID: 20651411
[TBL] [Abstract][Full Text] [Related]
10. Meeting report: tumor biology--how signaling processes translate to therapy.
Friedrich K; Janssen O; Hass R
Sci STKE; 2007 Apr; 2007(381):pe13. PubMed ID: 17426344
[TBL] [Abstract][Full Text] [Related]
11. Sex hormone receptors in breast cancer.
D'Abreo N; Hindenburg AA
Vitam Horm; 2013; 93():99-133. PubMed ID: 23810004
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
13. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Gralow J; Ozols RF; Bajorin DF; Cheson BD; Sandler HM; Winer EP; Bonner J; Demetri GD; Curran W; Ganz PA; Kramer BS; Kris MG; Markman M; Mayer RJ; Raghavan D; Ramsey S; Reaman GH; Sawaya R; Schuchter LM; Sweetenham JW; Vahdat LT; Davidson NE; Schilsky RL; Lichter AS;
J Clin Oncol; 2008 Jan; 26(2):313-25. PubMed ID: 18086794
[TBL] [Abstract][Full Text] [Related]
14. Drug development for cancer chemoprevention: focus on molecular targets.
Johnson KA; Brown PH
Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
[TBL] [Abstract][Full Text] [Related]
15. [MET signalling pathway and its therapeutic implications in gastrointestinal cancers].
Zaanan A; Laurent-Puig P; Taieb J
Bull Cancer; 2014 Jan; 101(1):25-30. PubMed ID: 24445683
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
17. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J
Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590
[TBL] [Abstract][Full Text] [Related]
18. Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications.
Driscoll JJ; Chowdhury RD
Cancer Lett; 2012 Dec; 325(2):147-54. PubMed ID: 22781397
[TBL] [Abstract][Full Text] [Related]
19. Targeted cancer therapy: promise and reality.
Klein S; Levitzki A
Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951
[TBL] [Abstract][Full Text] [Related]
20. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
